CoChat

Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme

Open access
Pedersen, Sue D., Giorgino, Francesco, Umpierrez, Guillermo, Thieu, Vivian T., Rodríguez, Angel, Nicolay, Claudia, Fernández Landó, Laura, Karanikas, Chrisanthi A., Kiljanski, Jacek · 2023 · Diabetes, Obesity and Metabolism
Cited by 22

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Aim: To assess the relationship between HbA1c and body weight reductions with tirzepatide treatment (5, 10 or 15 mg). Materials and Methods: HbA1c and body weight data at 40 weeks (SURPASS‐1, ‐2 and ‐5) and 52 weeks (SURPASS‐3 and ‐4) were analysed by trial. Results: Across the SURPASS clinical trials, HbA1c reductions from baseline were observed in 96%‐99%, 98%‐99% and 94%‐99% of participants treated with tirzepatide 5, 10 and 15 mg, respectively. Moreover, 87%‐94%, 88%‐95% and 88%‐97% of participants, respectively, experienced weight loss associated with HbA1c reductions. Statistically significant associations (correlation coefficients ranging from 0.1438 to 0.3130 across studies; P ≤ .038) between HbA1c and body weight changes were observed with tirzepatide in SURPASS‐2, ‐3, ‐4 (all doses) and ‐5 (tirzepatide 5 mg only). Conclusions: In this post hoc analysis, consistent reductions in both HbA1c and body weight were observed in most participants treated with tirzepatide at doses of 5, 10 or 15 mg. A statistically significant but modest association between HbA1c and body weight change was observed in SURPASS‐2, SURPASS‐3 and SURPASS‐4, suggesting that both weight‐independent and weight‐dependent mechanisms are responsible for the tirzepatide‐induced improvement in glycaemic control.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.15140

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 10

  1. Mounjaro [Press Release], 2022, European Commission Grants Marketing Authorisation for Lilly's Mounjaro® (Tirzepatide), the First GIP and GLP‐1 Receptor Agonist for Adults with Type 2 Diabetes in Europe
  2. 10.1016/S0140-6736(21)01324-6 · DOI · Paper page
  3. 10.1016/S0140-6736(21)02188-7 · DOI · Paper page
  4. 10.1007/s12325-018-0824-8 · DOI · Paper page
  5. Patel H, 2022, Tirzepatide‐induced weight‐loss in type 2 diabetes is independent of nausea, vomiting or diarrhoea, Diabetologia, 65
  6. 10.1111/dom.12660 · DOI · Paper page
  7. 10.1186/s12933-014-0171-2 · DOI · Paper page
  8. 10.1111/j.1463-1326.2012.01673.x · DOI · Paper page
  9. 10.4158/EP-2018-0444 · DOI
  10. 10.3390/ijms23105522 · DOI

Cited by

Metadata

Authors
Pedersen, S. D., Giorgino, F., Umpierrez, G., Thieu, V. T., Rodríguez, A., Nicolay, C., Fernández Landó, L., Karanikas, C. A., & Kiljanski, J.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2023-05-29
Volume
25
Issue
9
Pages
2553-2560
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W4378639993
Cited by
22
References
15
FWCI
3.47
Type
journal article
Language
en
Open access
hybrid
Funders
Eli Lilly and Company

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.